Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
FDA Defends Postmarket Drug Oversight, Amid Calls for Better Tracking May 4, 2012 Austin Kirk Add Your Comments Although critics suggest that the FDA is not doing enough to monitor side effects of drugs once they are approved, the agency maintains that it has been doing a much better job monitoring potentially dangerous drugs and informing the public and health officials when a problem arises. Last month, the FDA’s Center for Drug Evaluation and Research (CDER) released a report (PDF) highlighting the impact of a drug safety plan initiated in 2004 and the Food and Drug Administration Amendments Act of 2007, which gave the agency more authority to require post-market studies and demand label changes after drugs are approved. The FDA pointed to dramatic increases in drug safety communications, which the agency uses to issue warnings about drug side effects and to make people aware of new label warnings. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In 2010, the FDA issued 39 drug safety communications, but in 2011 that number almost doubled to 68 warnings. “Our oversight of the safety of marketed drugs has changed significantly over the past few years,” said Dr. Janet Woodcock, director of CDER. ” This report shows that the quality, accountability, and timeliness of postmarket drug safety decisions have been enhanced, and our public communication of this information is more effective.” The FDA statement was released just days before a report was released by the Institute of Medicine (IOM) of the National Academies, which found that the agency’s current approach to drug oversight after medications are approved is not sufficient and does not ensure that the benefits and risks of drugs are consistently monitored over the life cycle of the product. The IOM evaluated the scientific and ethical aspects of conducting safety studies for approved drugs at the FDA’s request, concluding that a regulatory framework should be adopted that could help make the agency’s decision-making process more predictable, transparent and proactive. Among recommendations include the use of a publicly available document to gather data about the drug over the entire time it is on the market. The document would describe the known side effects at the time of approval and highlight concerns that become evident as it is used by the public. It would also include all regulatory actions taken on the drug, including warnings, restrictions on use or post-marketing studies that have been ordered. The agency has faced a lot of criticism in recent years over its heavy reliance on postmarketing data, which some say turns the entire population of the United States into guinea pigs for drugs that should have been more thoroughly vetted during the clinical trial phase before they were ever approved. In addition, it is difficult for individuals considering new drugs to gather information on emerging safety signals. Two recent examples include the blood thinner Pradaxa and the diabetes drug Victoza. Pradaxa was introduced in October 2010 as a potential replacement for Coumadin, also known by its generic name warfarin. Within just a couple months, reports of deaths and severe bleeding events began rolling into the FDA’s adverse event reporting system. Coumadin has what is known as a reversal agent. If a patient begins bleeding too heavily, they can be given a dose of vitamin K to counteract the drug’s effects. Pradaxa has no reversal agent and bleeding events are much harder to stop. Recently, the FDA launched a safety investigation into the drug, but by then it was already entrenched in the market and has reportedly reached blockbuster status. Victoza, a diabetes drug by Novo Nordisk, was approved in January 2010 by the FDA, despite two of the agency’s own safety reviewers who called for the drug’s application to be rejected. The FDA ignored its drug safety staff’s advice and approved it for the market. Since the drug was released, the FDA has added additional safety warnings for thyroid cancer, pancreatitis, kidney failure, birth malformations and hypersensitivity. There were signs of thyroid cancer and pancreas problems during pre-approval process in human and animal clinical trials. More Lawsuit Stories Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials April 2, 2025 Nitrous Oxide Class Action Lawsuit Filed Over Fatal Side Effects of Flavored Gas Sold In Vape Shops April 2, 2025 Artificial Stone Cutter Files Lawsuit Over Silicosis Lung Disease April 2, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: today) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025) Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: yesterday) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025) Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: 2 days ago) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)
Nitrous Oxide Class Action Lawsuit Filed Over Fatal Side Effects of Flavored Gas Sold In Vape Shops April 2, 2025
Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: today) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025)
Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: yesterday) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)
Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: 2 days ago) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)